Siemens Healthineers Ag Stock Earnings Reports

Siemens Healthineers reported a solid start to fiscal 2026 and confirmed its full-year outlook. The company highlighted strong operational performance in its synergistic core — Imaging and Precision Therapy — driven by Photon Counting CT, PETNET activity and Varian, with operational margin expansion that largely offset tariff and FX headwinds. Diagnostics underperformed, primarily due to unexpected structural market changes in China (volume‑based procurement and reimbursement cuts) that materially reduced revenue and profit; Diagnostics revenue declined ~3% and China Diagnostics was the main drag. Management is progressing with preparations for deconsolidation from Siemens AG (including refinancing) and noted Moody’s investment‑grade rating as a milestone. The Elevating Health Globally strategy and value‑partnership model are gaining traction (examples: a 10‑year partnership in Arizona and strong adoption in Vietnam). Group revenue growth was ~3.8% in Q1, Americas grew strongly (~9%), China declined (~5%) driven by Diagnostics. Excluding tariffs and FX, operational margins expanded (group and segment‑level), and adjusted EPS (excluding headwinds) showed meaningful improvement; however tariffs and FX are expected to remain headwinds for the year (front‑loaded). For Q2 management expects group growth below the company’s 5–6% guidance range due to continued Diagnostics weakness in China and tough comparables, while Imaging and Precision Therapy growth should remain in mid‑single to mid/high‑single digits. Management reiterated confidence in mid‑term margins for the business mix overall but will monitor and may adjust Diagnostics assumptions depending on China developments.